Wordt geladen...
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
The main curative treatments for hepatocellular carcinoma (HCC) are surgical resection and liver transplantation, which only benefits 15% to 25% of patients. In addition, HCC is highly refractory and resistant to cytotoxic chemotherapy. Although several multi-kinase inhibitors, such as sorafenib, re...
Bewaard in:
| Gepubliceerd in: | Biomolecules |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7022495/ https://ncbi.nlm.nih.gov/pubmed/31936661 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom10010117 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|